The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Evolutionary Genomics are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak
Strong
Over the last 90 days Evolutionary Genomics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Evolutionary Genomics is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
Begin Period Cash Flow
215.8 K
Evolutionary
Evolutionary Genomics Relative Risk vs. Return Landscape
If you would invest 0.02 in Evolutionary Genomics on April 28, 2025 and sell it today you would earn a total of 0.00 from holding Evolutionary Genomics or generate 0.0% return on investment over 90 days. Evolutionary Genomics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Evolutionary, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Evolutionary Genomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evolutionary Genomics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Evolutionary Genomics, and traders can use it to determine the average amount a Evolutionary Genomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
Best Portfolio
Best Equity
Good Returns
Average Returns
Small Returns
Cash
Small Risk
Average Risk
High Risk
Huge Risk
FNAM
Based on monthly moving average Evolutionary Genomics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evolutionary Genomics by adding Evolutionary Genomics to a well-diversified portfolio.
Evolutionary Genomics Fundamentals Growth
Evolutionary Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Evolutionary Genomics, and Evolutionary Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evolutionary Pink Sheet performance.
By examining Evolutionary Genomics' fundamental ratios, stakeholders can obtain critical insights into Evolutionary Genomics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Evolutionary Genomics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. Evolutionary Genomics, Inc. was incorporated in 1990 and is based in Castle Rock, Colorado. Evolutionary Genomics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.
Things to note about Evolutionary Genomics performance evaluation
Checking the ongoing alerts about Evolutionary Genomics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Evolutionary Genomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Evolutionary Genomics generated a negative expected return over the last 90 days
Evolutionary Genomics has some characteristics of a very speculative penny stock
Net Loss for the year was (2.79 M) with loss before overhead, payroll, taxes, and interest of (1.23 M).
Evolutionary Genomics currently holds about 897.78 K in cash with (1.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 33.0% of the company shares are held by company insiders
Evaluating Evolutionary Genomics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Evolutionary Genomics' pink sheet performance include:
Analyzing Evolutionary Genomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evolutionary Genomics' stock is overvalued or undervalued compared to its peers.
Examining Evolutionary Genomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Evolutionary Genomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evolutionary Genomics' management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Evolutionary Genomics' pink sheet. These opinions can provide insight into Evolutionary Genomics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Evolutionary Genomics' pink sheet performance is not an exact science, and many factors can impact Evolutionary Genomics' pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Other Information on Investing in Evolutionary Pink Sheet
Evolutionary Genomics financial ratios help investors to determine whether Evolutionary Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evolutionary with respect to the benefits of owning Evolutionary Genomics security.